Siloxanes from the hydrolysis of isopropyltrimethoxysilane
摘要:
The behavior of isopropyltrimethoxysilane (1) in the presence one equivalent of water and a dibutyltin dilaurate catalyst has been investigated. Under these conditions, partial hydrolysis of the methoxy groups of 1 occurred, followed by condensation reactions leading to the formation of low molecular-weight oligomers. Disiloxane 4, trisiloxane 6 and cyclic siloxanes 7 and 8 have been isolated and fully characterized. Transient reaction intermediates silanol 3 and hydroxydisiloxane 5 have been characterized spectroscopically, The time evolution of these species was followed by gas chromatography and Si-29 NMR. A reaction scheme for the hydrolytic condensation of 1 is proposed to accommodate these results.
A nickel-catalyzed, enantioselective, three-component fluoroalkylarylation of unactivated alkenes with aryl halides and perfluoroalkyl iodides has been described. This cross-electrophile coupling protocol utilizes a chiral nickel/BiOx system as well as a pendant chelating group to facilitate the challenging three-component, asymmetric difunctionalization of unactivated alkenes, providing direct access
[EN] TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR_ARMS)<br/>[FR] MOLÉCULES DE RECRUTEMENT D'ANTICORPS CONJUGUÉS À UN AGONISTE DE TLR)
申请人:UNIV YALE
公开号:WO2013166110A1
公开(公告)日:2013-11-07
The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.
The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.